|

Relatlimab Clinical Trials

11 actively recruiting trials across 9 locations

Also known as: BMS 986016, BMS-986016, BMS-986016-01, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer +1 more

Pipeline

Phase 2: 9Phase 3: 1Phase 2/3: 1

Top Sponsors

  • National Cancer Institute (NCI)3
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
  • Bristol-Myers Squibb2
  • The Netherlands Cancer Institute1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer11
  • MSI-H Tumors1
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy1
  • Stage IV Bladder Urothelial Carcinoma AJCC v71
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v71

Other2 trials

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
Phase 2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Phoenix, Arizona1 trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Cancer Center at Saint Joseph's

Phase 2/3

Tucson, Arizona1 trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Southern Arizona VA Health Care System

Phase 3

Jonesboro, Arkansas1 trial

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Phase 2

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Los Angeles, California1 trial

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Cedars Sinai Medical Center

Phase 2

Baltimore, Maryland1 trial

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Johns Hopkins Hospital

Phase 2

Pittsburgh, Pennsylvania1 trial

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

UPMC Hillman Cancer Center

Phase 2

Houston, Texas1 trial

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.